Search clinical trials for: Durvalumab Tremelimumab

Total 778 results

Institut für Klinische Krebsforschung IKF GmbH...
Hannover Medical School; AstraZeneca

Recruiting

Durvalumab and Tremelimumab in Combination With Either Y-90 SIRT or DEB-TACE for Intermediate Stage HCC

HCC | Hepatocellular Carcinoma Non-resectable

Germany
AstraZeneca

Completed

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer (EAGLE)

Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN

United States, France, Italy, Spain, Belgium, Czechia, Romania, Taiwan, Korea, Republic of, Brazil, Hungary, Japan, Russian Federation, Australia, Germany, Israel, Serbia, Bulgaria, Ukraine, Argentina, Poland, Chile, Croatia, Georgia
The University of Hong Kong
Queen Mary Hospital, Hong Kong

Recruiting

Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma

Hepatocellular Carcinoma

Hong Kong
AstraZeneca

Completed

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC)

Non - Small Cell Lung Cancer NSCLC

United States, France, Germany, Italy, United Kingdom, Belgium, Poland, Romania, Taiwan, Thailand, Canada, Korea, Republic of, Czechia, Hungary, Japan, Russian Federation, Hong Kong, Spain, Netherlands, Greece, Australia, Serbia, Bu... and more
AstraZeneca

Active, not recruiting

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

Small Cell Lung Cancer

United States, Canada, Germany, Italy, Netherlands, Spain, Belgium, Poland, Taiwan, Vietnam, Korea, Republic of, Czechia, India, Japan, Russian Federation, Turkey, China, United Kingdom, Argentina
Terence Friedlander, MD
MedImmune LLC

Withdrawn

Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer

Bladder Cancer

United States
National Cancer Institute, Naples

Recruiting

Neo-adjuvant Chemo and Immunotherapy in The Pre-operAtive Treatment of Locally Advanced cholangIOcarciNoma

Cholangiocarcinoma

Italy
Canadian Cancer Trials Group
AstraZeneca

Completed

Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer

Colorectal Cancer

Canada
Catherine Shu

Withdrawn

Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment

Nonsmall Cell Lung Cancer

United States
University of Nebraska
AstraZeneca

Terminated

A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC

Small Cell Lung Carcinoma

United States
AstraZeneca

Completed

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

Spain, Poland, Hungary, Ukraine, Germany
AstraZeneca

Active, not recruiting

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

Urothelial Cancer

United States, Belgium, Denmark, Germany, Italy, Spain, Canada, Poland, Taiwan, France, Korea, Republic of, Netherlands, United Kingdom, Brazil, Japan, Mexico, Russian Federation, Turkey, China, Austria, Australia, Israel, Portugal, G...
Prisma Health-Upstate
AstraZeneca; MedImmune LLC

Recruiting

Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

Cancer | Rare Disease

United States
Federation Francophone de Cancerologie Digestive
AstraZeneca

Active, not recruiting

Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

Gastric Cancer | Gastric Adenocarcinoma

France
UNICANCER
Breast International Group

Completed

Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure (ULTIMATE)

Breast Cancer | Menopause | Estrogen Receptor Positive Tumor | Hormone Antagonist

France, Sweden, Spain
Sidney Kimmel Comprehensive Cancer Center at Johns...
AstraZeneca

Active, not recruiting

CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

Hepatocellular Carcinoma | Intermediate Stage of Hepatocellular Carcinoma

United States
Memorial Sloan Kettering Cancer Center
MedImmune LLC

Completed

Brain Irradiation and Tremelimumab in Metastatic Breast Cancer

Metastatic Breast Cancer

United States
Daniel George, MD
AstraZeneca

Withdrawn

TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer (TRIO Bladder)

Bladder Cancer

United States
NYU Langone Health
AstraZeneca

Withdrawn

Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer

Pancreatic Cancer

United States
AstraZeneca

Recruiting

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)

Muscle Invasive Bladder Cancer

Netherlands, United Kingdom, Korea, Republic of, Canada, Germany, Italy, Poland, Spain, Turkey, Vietnam, Argentina, Japan, France, Brazil, Taiwan, United States, Israel, Austria, Chile, Colombia, Greece, Hong Kong, Mexico, Portugal, Russian... and more
Jiping Wang, MD, PhD
AstraZeneca; Sirtex Medical

Recruiting

SIRT With Tremelimumab and Durvalumab for Resectable HCC

Hepatocellular Carcinoma | Hepatocellular Cancer | Resectable Hepatocellular Carcinoma

United States
Dana-Farber Cancer Institute
AstraZeneca

Terminated

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Recurrent Ovarian Carcinoma | Recurrent Cervical Carcinoma | Recurrent Endometrial Cancer | Metastatic Endometrial Cancer | Metastatic Cervical Cancer | Recurrent Vaginal Cancer | Recurrent Vulvar Cancer | Metastatic Ovarian Cancer | Recurrent Gynecological Cancer | Metastatic Vaginal Cancer | Metastatic...

United States
Ludwig Institute for Cancer Research
Boehringer Ingelheim; MedImmune LLC; PharmaJet, Inc.; CureVac; Cancer Research Institute...

Completed

Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC

NSCLC | Metastatic Non-small Cell Lung Cancer

United States
Institut für Klinische Krebsforschung IKF GmbH...

Active, not recruiting

Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

Intrahepatic Cholangiocarcinoma | Hilar Cholangiocarcinoma | Distal Cholangiocarcinoma | Gall Bladder Carcinoma | Biliary Tract Cancer (CCA)

Germany
Kyoto Breast Cancer Research Network

Terminated

Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer

Breast Cancer

Japan
Catherine Shu

Completed

SGI-110 Plus Durvalumab/Tremelimumab in SCLC

Extensive-stage Small Cell Lung Cancer

United States
Bayer

Recruiting

An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery (REFINE-IO)

Unresectable Hepatocellular Carcinoma

Greece, Brazil, China, Colombia, Italy, Korea, Republic of, Saudi Arabia, Spain, Taiwan, Thailand, United States, Argentina, France, Mexico, Turkey
Seoul National University Hospital

Active, not recruiting

Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer

Biliary Tract Neoplasms

Korea, Republic of
University of Alabama at Birmingham

Terminated

Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC) (ICC)

Cholangiocarcinoma

United States
Washington University School of Medicine
MedImmune LLC

Withdrawn

PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma (PIVOT-RCC)

Renal Cell Carcinoma
National Cancer Institute (NCI)

Completed

Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer

Pancreatic Neoplasms | Pancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the Pancreas

United States
Baki Topal
AstraZeneca

Active, not recruiting

Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer (MIMIPAC)

Pancreatic Cancer Non-resectable

Belgium
National Cancer Institute (NCI)

Completed

A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

Colorectal Neoplasms | Colorectal Cancer | Colorectal Carcinoma | Colorectal Adenocarcinoma | Refractory Cancer

United States
AIO-Studien-gGmbH
AstraZeneca

Completed

Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients (IMMUCHEC)

Cholangiocarcinoma | Cholangiocarcinoma Non-resectable | Gall Bladder Carcinoma | Gallbladder Carcinoma Non-Resectable

Germany
National Cancer Institute (NCI)

Completed

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Hepatocellular Carcinoma | Cholangiocarcinoma | Bile Duct Cancer | Biliary Tract Neoplasms | Liver Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
AstraZeneca

Active, not recruiting

Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States, Canada
Memorial Sloan Kettering Cancer Center
AstraZeneca

Recruiting

Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States
Georgetown University
AstraZeneca

Recruiting

Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma (ESR-22-21719)

Biliary Tract Cancer | Borderline Resectable Carcinoma

United States
Association Pour La Recherche des Thérapeutiques...

Active, not recruiting

NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma (NEMIO)

Infiltrating Bladder Urothelial Carcinoma

France
AstraZeneca

Completed

Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer (KESTREL)

Squamous Cell Carcinoma of the Head and Neck

United States, Canada, France, Italy, Spain, United Kingdom, Poland, Taiwan, Thailand, Vietnam, Belgium, Germany, Korea, Republic of, Brazil, India, Japan, Philippines, Russian Federation, Austria, Ukraine, Greece, Slovakia, Romania
MedImmune LLC

Active, not recruiting

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States, Italy, Spain, Taiwan, Korea, Republic of, China, Hong Kong, Japan, Singapore
University of Wisconsin, Madison
AstraZeneca

Terminated

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage IV

United States
AstraZeneca

Active, not recruiting

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NILE)

Metastatic Urothelial Cancer | Unresectable Locally Advanced Urothelial Cancer

United States, Italy, Spain, Canada, Hungary, Poland, Argentina, Thailand, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, India, Japan, Philippines, Russian Federation, China, Taiwan, Israel, Australia, Bulgaria
AstraZeneca

Active, not recruiting

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) (MYSTIC)

Non-Small-Cell Lung Carcinoma NSCLC

United States, Belgium, Spain, Canada, Taiwan, Thailand, Vietnam, France, Germany, Italy, Korea, Republic of, Hungary, Japan, Russian Federation, Netherlands, Australia, Switzerland
AstraZeneca

Completed

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Melanoma | Neoplasms | Renal Cell Carcinoma | Prostatic Neoplasms | Colorectal Neoplasms | Patients Who Have/Have Had Melanoma and Other Tumors

United States, United Kingdom
Canadian Cancer Trials Group
AstraZeneca

Recruiting

A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

Cancer

Canada
AstraZeneca

Active, not recruiting

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) (NEPTUNE)

Non Small Cell Lung Carcinoma NSCLC

Denmark, United Kingdom, United States, Poland, Brazil, India, Japan, Mexico, Peru, Russian Federation, Turkey, China, Malaysia, Hong Kong, Korea, Republic of, Chile, Israel, Ukraine, Portugal, Greece, Bulgaria, Philippines, Sweden, A... and more
Ludwig Institute for Cancer Research
Cancer Research Institute, New York City; MedImmune LLC

Completed

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Melanoma | Sarcoma | Breast Cancer | Solid Tumor | Prostate Cancer | Bladder Cancer | Head and Neck Squamous Cell Carcinoma | Cutaneous T-Cell Lymphoma | Renal Cancer | Merkel Cell Carcinoma | Testicular Cancer

United States
Noah Hahn, M.D.
AstraZeneca; Hoosier Cancer Research Network

Recruiting

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder (ADAPT-BLADDER)

Bladder Cancer | Urothelial Carcinoma

United States
Fundacion CRIS de Investigación para Vencer el...
AstraZeneca; Apices Soluciones S.L.

Completed

Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO) (DUTRENEO)

Bladder Cancer

Spain

Search clinical trials for: Durvalumab Tremelimumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations